drugset / Trial / NCT00215683
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study).
Timeline
- Start
- 2005-02
- Primary completion
- 2009-10
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 120 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 160 mg | Subcutaneous |